Sökning: id:"swepub:oai:gup.ub.gu.se/145516" >
On safety, pharmaco...
On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review.
-
- Hård, Anna-Lena, 1949 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation
-
- Hellström, Ann, 1959 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation
-
(creator_code:org_t)
- 2011-09-29
- 2011
- Engelska.
-
Ingår i: Acta paediatrica (Oslo, Norway : 1992). - : Wiley. - 1651-2227 .- 0803-5253. ; 100:12, s. 1523-1527
- Relaterad länk:
-
https://europepmc.or...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Off label intravitreal use of the VEGF antibody bevacizumab for retinopathy of prematurity (ROP) increases despite lack of studies on safety, pharmacokinetics and dosage in developing individuals. Systemic absorption has been considered negligible. A literature search was performed with emphasis on potential adverse systemic effects in developing individuals. Intravitreal bevacizumab enters the general circulation, suppresses plasma VEGF levels and remains in the blood for more than 8 weeks in primates. Possible adverse effects on VEGF dependent development must be considered.
Nyckelord
- Anti-vascular endothelial growth factor; Bevacizumab; Pharmacokinetics; Retinopathy of prematurity
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas